Abbott, GSK Add New Biomarker to Cancer Immunotherapy Companion Dx Agreement
December 01, 2011
Abbott, GSK Add New Biomarker to Cancer Immunotherapy Companion Dx Agreement
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Life Tech and GSK to Co-Develop qPCR-Based Companion Dx for Investigative Cancer Immunotherapy
October 27, 2011 / PCR Insider - Abbott, GSK to Develop PCR-Based Molecular Dx to Select Patients for Trial Skin Cancer Therapy
March 4, 2010 / PCR Insider - GSK/Abbott Pen Rx/Dx Co-Development Deal for MAGE-A3 Non-Small Cell Lung Cancer Treatment
July 15, 2009 / Pharmacogenomics Reporter - Insight Genetics Wins $1.5M Grant to Begin Clinical Testing for ALK Mutation CDx on Qiagen Platform
October 11, 2012 / PCR Insider - Pfizer, Abbott Ink Deal to Develop Companion Dx for PGx-based NSCLC Drug
September 2, 2009 / Pharmacogenomics Reporter